Loading…
LeonaBio, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -97.5% over 5Y.
today you would have $34.65▼ -96.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $7.57 | $5.87 | $24.30 | $31.70 | $130.30 | $342.50 | |
| P/B | 1.1x | 2.5x | 0.5x | 0.7x | 0.5x | 1.5x | 4.6x |
| EPS | -$24.70 | -$25.19 | -$30.90 | -$25.30 | -$14.90 | -$16.70 | |
| ROE | -65.53% | -380.03% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ELTXElicio Therapeutics, Inc. | $2.84 | — | 7.8x | — | -774.56% | $74.64M |
| NRXSNeuraxis, INC | $6.00 | — | 11.1x | — | -139.76% | $75.35M |
| RNXTRenovoRx, Inc. | $1.67 | — | 8.4x | — | -125.23% | $75.37M |
| OMOutset Medical, Inc. | $3.94 |
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Company description provided by Yahoo Finance.
| -216.19% |
| -90.39% |
| -40.67% |
| -17.08% |
| -7.28% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.8x |
| — |
| -59.17% |
| $74.06M |
| OSTXOS Therapies Inc | $1.64 | — | — | — | — | $76.21M |
| ANVSAnnovis Bio, Inc. | $1.72 | — | — | — | -703.68% | $73.28M |